Innovation and M&A to boost these stocks
There’s been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Overall, 12 mental health disorders affect 970 million people around the world — or one…
This little-known biopharma stock has 60% upside potential, Goldman Sachs says
Investors should consider putting money in Xenon Pharmaceuticals , a biopharma stock poised to rally as Wall Street gains more clarity on its drug to treat epilepsy, Goldman Sachs says.…